

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



64

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68, C12P 19/34, G01N 33/553, 33/544, B05D 1/00, C07H 21/02, 21/04		A1	(11) International Publication Number: WO 98/27229
			(43) International Publication Date: 25 June 1998 (25.06.98)
(21) International Application Number: PCT/US97/23242			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IR, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 16 December 1997 (16.12.97)			
(30) Priority Data: 08/768,893 17 December 1996 (17.12.96) US			
(71) Applicant: THE UNIVERSITY OF CHICAGO [US/US]; 5801 S. Ellis, Chicago, IL 60637 (US).			
(72) Inventors: MIRZABEKOV, Andrei Darievich; Apartment 1, Porfsoyuznaya Street 43, Moscow, 117420 (RU). DUBI- LEY, Svetlana A.; Engelhardt Institute of Molecular Biol- ogy, Vavilov Street 32, Moscow, 117984 (RU). LYSOV, Yuri Petrovich; Apartment 292, Yeniseiskaya Street 10, Moscow, 129344 (RU).			
(74) Agent: CHERSKOV, Michael, J.; Cherskov & Flaynik, The Civic Opera Building, Suite 1447, 20 North Wacker Drive, Chicago, IL 60606 (US).			Published <i>With international search report. Before the expiration of the time limits for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD OF DNA SEQUENCING BY AFFINITY FRACTIONATION AND ARRAY HYBRIDIZATION			
(57) Abstract <p>A method for fractionating and sequencing DNA via affinity interaction is provided comprising contacting cleaved DNA to a first array of oligonucleotide molecules to facilitate hybridization between said cleaved DNA and the molecules; extracting the hybridized DNA from the molecules; contacting said extracted hybridized DNA with a second array of oligonucleotide molecules, wherein the oligonucleotide molecules in the second array have specified base sequences that are complementary to said extracted hybridized DNA; and attaching labeled DNA to the second array of oligonucleotide molecules, wherein the labeled re-hybridized DNA have sequences that are complementary to the oligomers. The invention further provides a method for performing multi-step conversions of the chemical structure of compounds comprising supplying an array of polyacrylamide vessels separated by hydrophobic surfaces; immobilizing a plurality of reactants, such as enzymes, in the vessels so that each vessel contains one reactant; contacting the compounds to each of the vessels in a predetermined sequence and for a sufficient time to convert the compounds to a desired state; and isolating the converted compounds from said array.</p>			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD OF DNA SEQUENCING BY AFFINITY FRACTIONATION AND ARRAY HYBRIDIZATION

CONTRACTUAL ORIGIN OF THE INVENTION

The United States Government has rights in this invention pursuant to Contract No. W-31-109-ENG-38 between the U.S. Department of Energy and the University of Chicago representing Argonne National Laboratory.

5

BACKGROUND OF THE INVENTION1. Field of the Invention

This invention relates to miniaturized reaction vessels and the use of such vessels and more specifically, this invention relates to miniaturized reaction vessels and arranging the vessels in an array for performing various biochemical procedures that require at least one reactant to be attached to a solid substrate.

10

2. Background of the Invention

The need to contain and manipulate small quantities of reactants is widespread. For example, forensic activities often deal with micro-quantities of DNA, bodily fluids, explosives, pesticides, microorganisms, toxins and other residues in trace amounts. Enzyme-linked immunoadsorbent assay (ELISA) procedures are such situations where small quantities of reactants are utilized.

15

Currently, devices exist to facilitate the containment and mixing of small quantities of reactants. Some of these devices include microtiter plates and microwell plates having reaction volumes in the range of 1 to 10

20

microliters. Such devices are frequently used in situations where one of the reactants need to be immobilized.

However, there are some instances where smaller reaction volumes are required (i.e., between approximately 0.1 nanoliters and 100 nanoliters) or where increased density of the immobilized component is sought for the purpose of increasing reaction output. In addition, economics often dictate limited use of mobile reactants viz. the immobilized fraction, particularly where the liquid state reactants are available in limited quantities. In such scenarios, concentrations of the reactants can be increased when the total necessary volume of the solvent decreases.

There are also instances where site-specific manipulation of molecules and construction of molecular combinations is desired, taking into consideration tendencies of repulsion, aggregation, steric hindrances, etc. Such instances would require multi-step procedures at the same molecular site and under the same reaction conditions.

Currently, no device or procedure exists to facilitate molecular interactions of the types mentioned supra.

A need exists in the art for a device to contain nanoliter quantities of reactants to facilitate specific interactions between the reactants. The reaction vessel must be designed to exploit steric and solution limitations associated with instances where specific molecules are manipulated. Finally, the device must be constructed with widely available materials and also must be easy and economical to use.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a miniaturized reaction vessel that overcomes many of the disadvantages of the prior art.

Another object of the present invention is to provide a device which facilitates the immobilization of one or a plurality of reactants. A feature of the invention is a plurality of isolated reaction vessels arranged in a predetermined configuration. An advantage of the invention is that each vessel serves as a separate reaction chamber so that the plurality of reaction chambers can be utilized simultaneously to facilitate in parallel fractionation and enzymatic modification, and other modification of target reactants and

molecules.

Still another object of the present invention is to provide a method for using an array of miniaturized reaction vessels to facilitate affinity capture procedures. A feature of the invention is treating each vessel as a chromatography micro-column to be used simultaneously. An advantage of the invention is facilitating the fractionation of a mixture of DNA molecules of known and unknown primary structure, as well as other molecules.

Yet another object of the present invention is to provide a method to facilitate simultaneous multi-chemical reaction processes with many different substrates. A feature of the invention is that specific enzymes react with different or the same substrates that are separated from each other and placed or immobilized within separate, miniaturized reaction chambers which in turn are arranged in a predetermined configuration. An advantage of the invention is that it allows for controlled-multi-step conversions of various compounds and analytes. Another advantage is that when a substrate is confined to a single reaction chamber, site-specific biochemical reactions can be performed.

Another object of the present invention is to provide a method for fractionating and sequencing DNA molecules. A feature of the invention is the use of oligonucleotide arrays to first isolate the target DNA sequence and then the use of a second oligonucleotide array to sequence the isolated DNA more efficiently. An advantage of the invention is the obviation of costly intermediate cloning and mapping steps used in typical sequencing processes.

Still another object of the present invention of the present invention is to provide a protein affinity assay method. A feature of the invention is the isolation and immobilization of different proteins, such as antibodies, in specific elements of an array and then exposing the array to a particular protein or antigen. An advantage of the present method is the ability to conduct thousands of assays simultaneously thereby providing a universal diagnostic chip, such as for antibody screening.

Briefly, the invention provides a method for conducting affinity fraction-

ation and sequencing of DNA comprising cleaving DNA into predetermined lengths; labeling the cleaved DNA; contacting the labeled DNA to a first array of isolated oligonucleotide sequences, wherein said sequences are complementary to portions of the DNA; allowing hybridization to occur between said
5 cleaved DNA and the sequences; extracting the hybridized DNA from the sequences; contacting said extracted hybridized DNA with a second array of immobilized oligonucleotide molecules, wherein some of the oligonucleotide molecules in the second array have base sequences that are complementary to said extracted hybridized DNA; allowing the extracted hybridized DNA to
10 re-hybridize with the second array of oligonucleotide molecules; and attaching labeled oligomers to the second array of oligonucleotide molecules, wherein the labeled oligomers have sequences that are complementary to the re-hybridized DNA.

The invention further provides a method for performing multi-step
15 conversions of compounds comprising supplying an array of polyacrylamide vessels separated from each other by a hydrophobic surface; immobilizing a plurality of reactants in the vessels so that each vessel contains one reactant; contacting the compounds to each of the vessels in a predetermined sequence and for a sufficient time to convert the compounds to a desired state;
20 and if required, isolating the converted compounds from said array.

The invention also provides a method for manipulating nanoliter quantities of molecules comprising removably attaching the molecules to a polyacrylamide vessel having a predetermined nanoliter-scale volume, wherein the molecules are confined to the volume; introducing into the vessel
25 a means to modify the molecules; removing the modifying means from the vessel; and isolating the now modified molecules from the vessel.

BRIEF DESCRIPTION OF THE DRAWING

The invention together with the above and other objects and advantages will be best understood from the following detailed description of
30 the preferred embodiment of the invention shown in the accompanying drawing, wherein:

FIG. 1 is a schematic diagram of the invented method, in accordance with the present invention;

FIG. 2 is a table of DNA hybridization probability values, in accordance with the present invention;

FIG. 3 is a conceptual view of interactions between reactants contained in the invented miniaturized vessel, in accordance with the present invention;

FIG. 4 is a schematic view of arrays of fractionation vessels containing products of reactions, such as fractionated DNA, in accordance with the present invention;

FIG. 5 is a conceptual view of oligonucleotide phosphorylation and ligation reactions facilitated by miniaturized reaction vessels, in accordance with the present invention; and

FIGS. 6A-C are schematic views of arrays of reaction vessels containing products of oligonucleotide phosphorylation and ligation reactions, in accordance with the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have developed a process to perform hybridization, fractionation and enzymatic manipulation of molecules in a site specific way. The technique utilizes oligonucleotide chips arranged as high density arrays. The combination of the above-identified reactions into a simplified procedure obviates the need for intermediate mapping and cloning of fractionated products. As such, this new technique is a radical departure from typical sequencing processes.

Generally, the invented process for fractionating, sequencing, and enhancing target DNA is depicted in FIG. 1 as numeral 10. A first step is the cleavage of a specific single-strand DNA molecule 14 with restriction enzymes R1 and R2 to create a plurality of sets of fragments, wherein fragments of one set overlap fragments of another set. In FIG. 1, two sets of fragments are depicted, with one set having fragments I, II and III, and another set having fragments A, B and C. Then, the sets of fragments are loaded onto an array 16 or plurality of arrays containing a plurality of gel elements. Each gel element 18 contains a different immobilized oligonucleotide string of specific length and sequence that is complementary to a portion of the fragmented DNA.

After allowing the fractionated DNA to hybridize with complementary sequences, the hybridized DNA from a specific gel element 18 is extracted from the element 18. The extracted DNA could be labeled at this point and then placed on a second array 20 containing individual gel elements 20i, 20ii, 20iii, etc., each gel element known to contain a specific isolated immobilized oligomer. In FIG. 1, a second array 22 also is depicted containing immobilized oligomer complementary to fragment II.

The second array 20 is scrutinized for the presence of the label. Those specific gel elements, 20i, that contain labeled oligomers indicate that complete hybridization of the target DNA fragment 22 has occurred. The overlapping of these perfectly hybridized oligonucleotides enables one to reconstitute the DNA sequence. Therefore, invented method provides for efficient fractionation and sequencing of DNA.

As noted above, the process of sequentially manipulating molecules involves the use of miniaturized reaction vessels. Generally, each vessel consists of a specific volume or construct of polyacrylamide, whereby the polyacrylamide construct is immobilized on a hydrophobic surface such as glass.

Each construct can range in size from approximately 0.06 x 0.06 x 0.02 millimeter to 1 x 1 x 0.02 millimeter. Each construct serves as a 70 picoliter (picoliter = 10^{-12} liter) or a 20 nanoliter (nanoliter = 10^{-9} liter) micro-test tube in as much as the constructs are arranged relative to each other in an array on a hydrophobic surface.

Array Manufacturing Detail

The construct array is manufactured via a modified Methylene Blue induced photo-polymerization procedure whereby a polyacrylamide solution is prepared and then configured into gel pad molds having the desired shapes and sizes for subsequent polymerization. After polymerization, a specific oligonucleotide is applied and chemically modified to each gel pad. A detailed description of the array manufacturing procedure is contained in a co-pending U.S. patent application, having serial number 08/592,120, assigned to the instant Assignee, and incorporated herein by reference.

DNA Fractionation

Complementary interactions are effectively used for affinity fractionation of nucleic acids by hybridization with a complementary strand immobilized on a solid support. Fractionation on an oligonucleotide array is an alternative to DNA cloning for isolating specific fragments from DNA digests.

5 Chip fractionation is followed by conventional sequencing or by sequencing by hybridization with oligonucleotide chips. In the later scheme, devised by the inventors, DNA is first digested with restriction endonucleases, then the fragments are fractionated on the oligonucleotide chip and finally transferred from this chip onto a sequencing microchip.

10 Three scenarios can be considered in this scheme. In the first scenario, approximately 16 to 120 fragments having an average length of 250 bases are generated by cutting cloned plasmid or cosmid DNA respectively, with 4 bp-long specific restriction endonucleases. These fragments can be sequenced by conventional gel methods or by using sequencing microchips.

15 In the second scenario, the cosmid, BAC and YAC DNAs are digested into about 8, 25, and 125 fragments of about 4,000 bases with the use of 6 bp-long specific restriction endonucleases. These fragments can be directly sequenced following the chip fractionation by the "walking primer" procedure or by the use of contiguous stacking hybridization on a sequencing microchip,

20 as disclosed in U.S. Patent Application No. 08/587,332, and incorporated herein by reference. In the third scenario, bacterial DNA are specifically split into 100 fragments of the Cosmid size. The fractionated products are then treated by the processes outlined in the first or second scenarios, discussed supra.

25 To effectively separate the fragments from each other, each gel element of an array must contain oligonucleotide strings that are unique for specific fragments. The longer the oligonucleotide string and the shorter the fragmented DNA, the higher the probability that a sequence complementary to the oligonucleotide string will be unique for only one of the fragments.

30 Concurrently, the probability P that the oligonucleotide string will hybridize at all with any fragment present in the mixture, will be lowered. The use of longer oligonucleotide strings increases the fractionation efficiency but this

demands larger chips.

Conversely, the shorter the length of immobilized oligonucleotide strings, the higher the hybridization sensitivity to single-base-pair mismatches; however, the stability of the formed duplexes decrease. Furthermore, single-stranded nucleic acids form relatively stable hairpins and tertiary structures that interfere with their hybridization with shorter oligonucleotide immobilized fractions. The inventors have found that the introduction of base analogs or the substitution of negatively charged phosphodiester groups in the immobilized oligonucleotides for some neutral or even positively charged groups significantly increases duplex stability viz. hairpin stability. For example, substitution of negatively charged phosphate groups for positively charged guinidinium linkages renders the duplex of thymidil 5-mers with poly(rA) stable even in boiling water.

The inventors have made probability calculations to balance fractionation efficiency with chip complexity. These calculations are presented in FIG. 2. Briefly, FIG. 2 provides the calculated values for the numbers N and n of oligonucleotides of length m , such lengths ranging from 6-mer (i.e. hexamers) to 11-mers (i.e. undecamers). The calculated values are specific for an array capable of fractionating a mixture of a specific number (K) of random sequenced, DNA fragments having a length l , with 90 percent, 95 percent and 99 percent probability. Fragments of about 250 and 4,000 bp are generated when DNA cloned in YACs, BACs, cosmids and plasmids are digested by restriction endonucleases specific for 4 and 6 bp cleavage, respectively.

N signifies the minimal number of oligonucleotides in such an array wherein each fragment is bound at a specified probability to any gel pad which binds no other fragments. Numbers n' and n designated the number of oligonucleotides among N that bind, respectively, the only one or one and more fragments. The ratio n'/n represents the efficiency of the array by indicating the share of such cells which participate in DNA binding and which contain only one fragment from the mixture.

The table in FIG. 2 can be utilized as follows: As can be noted in line 1

of FIG. 2, to fractionate sixteen 250 bp-long fragments of plasmid DNA (4,000 bp in length) at 90 percent probability, gel arrays containing 96 properly selected non-correlating 6-mers need to be employed. Among these 96 hexamers, fifty nine will bind DNA, with 61 percent of those fifty nine (according to a 61 percent probability estimated at the far right of the table), or 36 hexamers, isolating a single fragment from the mixture.

Fractionation of a complex mixture of DNA fragments may require large arrays. For example, and as can be noted in line 5 of FIG. 2, to separate 125 DNA fragments of plasmid size in the digest of 500,000 bp long YAC DNA with 99 percent probability, the fractionation array would require 1,918 oligonucleotides of 10-base lengths. The size of such a complex array is approximately 9 centimeters X 9 centimeters, if each gel element is 1 x 1 mm and if the elements have 2 mm center-to-center spacings relative to each other.

In such instances, fractionation and specific fragmentation can be carried out in two rounds to obtain DNA fragment sizes that are manageable for sequencing. For example, as can be noted in line 6 of FIG. 2, 4,000,000 bp-long genomic DNA of *E. coli* could be fractionated using an array containing 1,557 oligonucleotides to produce approximately 125 fragments of a cosmid's size (30,000 bp). As can be noted in line 3 of FIG. 2, these cosmid-size fragments can be digested further to approximately 4,000 bp-fragments with arrays containing 118 or 116 oligomers of 7-mer or 8-mer lengths, respectively.

DNA digestion with at least two different restriction endonucleases should be performed to obtain overlapping sequences. Then each digest should be fractionated and sequenced to reconstitute the DNA sequence from the structure of the overlapping fragments.

To fractionate double-stranded DNA, each chip element should contain oligonucleotide strings complementary to each target strand. However, if one needs to separate both complementary DNA strands, the complementary oligonucleotides should be immobilized in different microchip pads. This will necessitate a doubling of the number of gel elements in the array.

An efficient fractionation of single-stranded DNA was carried out by its hybridization with a chip containing gel-immobilized decamers. DNA was extracted separately from each decamer gel cell, transferred onto a sequencing microchip and analyzed thereon. In the phosphorylation sequence, decamers of the chip were enzymatically phosphorylated, then hybridized with DNA and ligated with a pentamer in a site directed manner. This enhanced the efficiency of sequence analysis by increasing the length of specified oligonucleotides of the chip. Overall, the invented techniques illustrate the efficiencies for analyzing DNA and for the sequencing of long DNA without the need for intermediate cloning and mapping.

Three nested fragments F1, F2, and F3, all shown in FIG. 3, were amplified separately with fluorescently labeled sense primers (5'-TMR-gtggagccacacccctagg-3') for F1, 5'-TMR-agaagtctgccgttactgcc-3' for F2, 5'-TMR-gtggagacagagaagactcttg-3' for F3 fragments and antisense primers (5'-acttttatgccagccctg-3' for F1, 5'-ccttgatccaacctgccc-3' for F2, 5'-aaaatagaccaataggcagagagag-3' for F3 fragments). Reaction mixtures contained 50 nanograms (ng) of 421 base pair (bp) long DNA-target and corresponding primers. Amplifications were carried out in 30 cycles: 94 °C for 30 seconds, 50 °C for 40 seconds, 72 °C for 20 seconds. 3 µl of each PCR mixture were used for single primer reamplification with corresponding fluorescently labeled sense primers. 40 cycles of amplification were carried out under the conditions described in Yershov G. et al., (1996) *Proc. Natl. Acad. Sci. USA*, 93, 4913-4918, and incorporated herein by reference. 50 µl of each PCR mixture were precipitated separately with 500 µl of 0.2 M LiClO₄ in acetone, and the remaining 50 µl of each mixture were combined in a single tube and also precipitated. The pellets were washed with acetone and dissolved in hybridization buffer (1M NaCl/1 mM EDTA/10 mM Na-phosphate, pH 6.8)

Three decamers (15 pmol each) f1, f2, and f3 complementary to F1, F2 and F3 respectively (as shown in FIG. 3), were immobilized on 1 x 1 x 0.02 mm gel elements of a fractionation array, as depicted in FIG. 4A.

2 µl of fluorescently labeled F1, F2, and F3 and a mixture thereof were

separately hybridized with the fractionation chip at 4 °C in hybridization buffer to remove non-hybridized DNA. Non-specifically bound DNA was washed off with hybridization buffer at 15 °C for 5 minutes.

5 DNA fragments were eluted separately at 40 °C with 3 μ l of hybridization buffer from each of three F1-3 elements of the fractionation chip and hybridized with each of three clusters of the sequencing microchip (FIG. 4B) under the same conditions as described above. The sequencing array (FIG. 4B) contained three identical clusters consisting of nine decamers that were complementary to F1, F2, or F3. Fluorescence hybridization images of
10 fractionation and sequencing chips were monitored with a fluorescence microscope equipped with a CCD camera and software, as disclosed in Yershov, et al., noted supra.

FIG. 4B shows that each DNA isolated from the mixture on the gel elements f1, f2 or f3 is hybridized only with the corresponding sequencing set
15 of decamers and thus can be unambiguously identified. Cross-hybridization of the decamers with DNA of the other two fractions was negligible. These results demonstrate how the invented miniaturized reaction vessel promotes high efficiency DNA fractionation and suitable accuracy of sequence analysis on sequencing gels comprising similar vessels.

20 Phosphorylation Detail

Due to the hydrophobic spacing 20 between the gel elements 22, site-directed reactions can be carried out selectively in specified elements of the chip.

50 pmole of synthetic oligonucleotide (5'-ataccaacct-r³²P-U-3') was
25 phosphorylated with 10 μ l of reaction mixture containing 1xPNkinase buffer (66 mM K-acetate, 10 mM Mg-acetate/5 mM dithiothreitol/33 mM Tris-acetate, pH 7.8), 15 μ Ci [γ -³²P] ATP, 500 pmole ATP and 0.5 U T4 Polynucleotide Kinase, available from Epicentre Technologies, Madison, WI, at 37 °C for 60 minutes.

30 The ³²P-labeled decamer (depicted in FIG. 5) was immobilized within a 1 x 1 x 0.02 mm gel construct, labeled as "a" in FIG. 6A and the same non-phosphorylated oligonucleotide was immobilized within the constructs labeled as "b", "c" and "d" in FIGS. 6B, 6C, and 6D, respectively, at a concentration of

5 pmole of oligonucleotide per construct.

Immobilization was carried out at 20 °C for 12 hours. The array 6a containing the phosphorylated oligonucleotide was washed with washing buffer (0.2 M NaCl/0.2 mM EDTA/2 mM Na-phosphate, pH 6.8) at 37 °C for 1 hour and then rinsed with water. The chip was dried and radio-autographed with Kodak Scientific Imaging Film X-OMAT™ (Eastman Kodak, Co., Eastman, TN)

1 µl of phosphorylation mixture [1.5 µCi [γ -³²P] ATP, 50 pmol ATP and 0.05 U T4 Polynucleotide Kinase in 1 x PNkinase buffer (Epicentre Technologies, USA)] was added to gel element B. As a control, the same mixture, excluding Kinase, was added to gel element c. An alternative control is the addition of 1 µl of 1 x PNkinase buffer added to gel element "a." Enzymatic phosphorylation is carried out at 37 °C for 3 hours at 100 percent humidity. The chip was washed first with washing buffer (0.2 M NaCl/0.2 mM EDTA/2mM Na-phosphate, pH 6.8) at 37 °C for one hour, then with water, dried and radio-autographed.

As is illustrated in FIG. 6B, the ³²P label appeared only on gel element "b" with no cross contamination to gel elements c or d being observed. This illustrates the efficiency of phosphorylation of the gel-immobilized oligonucleotide.

Ligation Detail

3 µl of a ligation mixture was prepared, containing 10 pmol of ssDNA 5'-tgggcagggttggtatcaaggt-3' (complementary to the immobilized decamer), 50 pmol of fluorescently labeled pentamer 5'-HEX-ccttg-3' (stacked to the immobilized decamer), 1 mM ATP, and 0.1 U T4 DNA Ligase (available from Epicentre, Technologies, Madison WI) in 1 x T4 DNA Ligase buffer (6.6 mM K-acetate/10 mM Mg-acetate/33 mM Tris-acetate, pH 7.8). These reactants were added to each of the "b" and "c" gel elements in FIG. 6C. Ligation was carried out at 4 °C for 5 hours, then the chip was washed with washing buffer (0.2 M NaCl/0.2 mM EDTA/2 mM Na-phosphate, pH 6.8) at 10 °C for 5 minutes. Fluorescence hybridization on the chip was monitored with a fluorescence microscope, per the technique outlined in Yershov, supra.

As can be noted in 7C, the fluorescence label is observed only in gel

element "b" of FIG. 6C. As with the phosphorylation procedure above, the miniaturized vessels facilitate site directed ligation.

Oligonucleotide
Loading Detail

5 The inventors have developed a specific method for loading oligonucleotides onto the miniaturized reaction vessels. The method is fully disclosed in PCT/RU 9400179, and incorporated herein by reference. Described briefly, a pin is immersed into, and is wetted with, oligonucleotide solution. After being withdrawn from the solution, the pin is contacted with the
10 gel surface.

During oligonucleotide aspiration, transfer and deposition, the temperature of the pin must be maintained near dew point at ambient temperature so as to prevent evaporation. Otherwise, the viscosity of the solution micro-volumes (typically 10 nanoliters or less) will lead either to complete
15 evaporation or to incomplete transfer of the desired dose.

The invented transfer method allows for the transfer of a range of micro-volumes of oligonucleotide solutions, from 0.3 to 50 nanoliters (nl), with a dispensing error of no more than approximately ± 20 percent.

Oligonucleotide Immobilization Detail

20 The inventors have developed an immobilization procedure for coupling micromolecules to acrylamide gels so as to minimize liquid evaporation during immobilization and to also ensure that covalent bonding of oligonucleotides to the gel matrix units proceeds to completion. This procedure is more fully disclosed in PCT/RU 9400178 and incorporated
25 herein by reference.

Briefly, the immobilization process is as follows: Micro-volumes of bioorganic solutions are loaded onto the micro-matrix cells, with the temperature of the micro-matrix being maintained equal to that of the ambient air. Once the micro-volumes of the oligonucleotide solutions have been
30 applied to the cells of the matrix, the micro-matrix temperature is set equal to or below the dew point of the ambient air. This temperature is maintained until swelling of the gel is complete and non-coalescent droplets of water condensate appear in the spacings between the gel pads.

After the appearance of the water condensate, a thin layer of an inert, non-luminescent oil is applied to the micro-matrix surface so as to prevent oligonucleotide evaporation.

The micro-matrix is kept under the oil layer until completion of the oligonucleotide immobilization process, and preferably for 48 hours. The oil is then removed by washing with a polar substance that will not cause oligo denaturing, such as ethanol, or water. The matrix is dried and stored indefinitely, ready for use.

Probability Calculations

The probability, q , for a fragment with the random sequence of length l to get into a fractionating cell containing immobilized m -mers can be described by the relation $q = 1 - (1 - 1/(4^m))^{l \cdot m + 1}$, hence, the corresponding probability of its not getting into a cell of same kind is $q = 1 - (1 - 1/(4^m))^{l \cdot m + 1}$.

With K fractions available, the probability that at least one fragment will get into a randomly chosen fractionating cell is expressed as $P_{s,1} = 1 - q^K$. For N non-correlating fractionating cells, the expected average number of filled cells can be written as $n = N \cdot P_{s,1}$. At the same time, the expected probability for a single fragment getting into the cell is determined by the relation $P_1 = K \cdot q \cdot q^{K-1}$.

The ratio of cells with the one fragment to all filled cells is given by $n^1/n = P_1/P_{s,1}$.

While the invention has been described with reference to details of the illustrated embodiment, these details are not intended to limit the scope of the invention as defined in the appended claims.

For example, the invented method is appropriate for drug screening or to construct a protein assay. In one scenario, a myriad of monoclonal antibodies, heavy and light chains from a spleen library is a suitable source, is accumulated via polymerase chain reaction processes. Then each of these antibodies are immobilized in separate gel elements of an array. The array is then subjected to an antigen which is tagged. Those gel elements that light up would serve as starting points for building antibodies specific for that

antigen. Further, depending on the size of the array, such arrays of gel cells, or microchips, could serve as a universal antibody diagnostic chip allowing for thousands of assays to occur simultaneously via protein affinity processes.

The embodiment of the invention in which an exclusive property or privilege is claimed is defined as follows:

- 1 1. A method for conducting affinity fractionation and sequencing of
2 DNA comprising:
 - 3 a.) cleaving DNA into predetermined lengths;
 - 4 b.) labeling the cleaved DNA;
 - 5 c.) contacting the labeled DNA to a first array of isolated
6 oligonucleotide sequences, wherein said sequences are complementary to
7 portions of the DNA;
 - 8 d.) allowing hybridization to occur between said cleaved
9 DNA and the sequences;
 - 10 e.) extracting the hybridized DNA from the sequences;
 - 11 f.) contacting said extracted hybridized DNA with a second
12 array of immobilized oligonucleotide molecules, wherein some of the
13 oligonucleotide molecules in the second array have base sequences that are
14 complementary to said extracted hybridized DNA;
 - 15 g.) allowing the extracted hybridized DNA to re-hybridize with
16 the second array of oligonucleotide molecules; and

17 h.) attaching labeled oligomers to the second array of
18 oligonucleotide molecules, wherein the labeled oligomers have sequences
19 that are complementary to the re-hybridized DNA.

1 2. The method as recited in claim 1 wherein the DNA is selected
2 from the group consisting of plasmid DNA, cosmid DNA, bacterial DNA,
3 eucaryotic DNA, and combinations thereof.

1 3. The method as recited in claim 1 wherein the first array and
2 second array of oligonucleotide molecules further comprise:
3 a plurality of polyacrylamide gel elements, with each gel element
4 hydrophobically isolated from the other gel elements; and
5 at least one oligonucleotide molecule attached to the gel element.

1 4. The method as recited in claim 1 wherein the first
2 oligonucleotide molecules are between 6 and 12 bases long.

1 5. The method as recited in claim 1 wherein the DNA molecules
2 are between 200 and 4,000,000 bases long.

1 6. The method as recited in claim 1 wherein the step of attaching
2 labeled oligomers to the array of oligonucleotide molecules further comprises:
3 h.) phosphorylating the array molecules; and
4 i.) ligating the labeled oligomers to the phosphorylated molecules.

1 7. A method for performing multi-step conversions of compounds
2 comprising:
3 a.) supplying an array of polyacrylamide vessels;
4 b.) immobilizing a plurality of reactants in the vessels so that each
5 vessel contains one reactant;
6 c.) contacting the compounds to each of the vessels in a
7 predetermined sequence and for a sufficient time to convert the compounds

8 to a desired state; and

9 d.) isolating the converted compounds from said array.

1 8. The method as recited in claim 7 wherein the compounds are
2 selected from the group consisting of nucleic acids, proteins, antibodies,
3 peptides, low molecular weight compounds, and combinations thereof.

1 9. The method as recited in claim 7 wherein the compounds are
2 DNA.

1 10. The method as recited in claim 7 wherein the reactants are
2 enzymes.

1 11. The method as recited in claim 10 wherein the reactants are
2 enzymes selected from the group consisting of phosphorylation enzymes,
3 endonucleases, exonucleases, ligase, RNA polymerase, DNA polymerase,
4 and combinations thereof.

1 12. The method as recited in claim 7 wherein the capacity of the
2 vessels is between approximately 0.01 nanoliters and 100 nanoliters.

1 13. The method as recited in claim 7 wherein the vessels are
2 isolated from each other by a hydrophobic region.

1 14. The method as recited in claim 7 wherein the compounds are
2 contacted to each of the vessels to facilitate affinity interactions between the
3 compounds and the reactants.

1 15. A method for manipulating nanoliter quantities of molecules
2 comprising:
3 a.) removably attaching the molecules to a polyacrylamide vessel
4 having a volume of from a fraction of nanoliter to hundreds of nanoliters,

- 5 wherein the molecules are held in a confined volume;
6 b.) introducing into the vessel a means to modify the molecules;
7 c.) removing the modifying means from the vessel; and d.)
8 isolating the now modified molecules from the vessel.

1 16. The method as recited in claim 15 wherein the molecules are
2 selected from the group consisting of nucleic acids, oligonucleotides, proteins
3 amyloid-forming proteins, antibodies, synthetic peptides, low molecular weight
4 compounds, and combinations thereof.

1 17. The method as recited in claim 15 wherein the molecules are
2 DNA and the means to modify the molecules is a phosphorylation reaction.

1 18. The method as recited in claim 17 wherein the DNA molecules
2 are contacted with a mixture of phosphate and a phosphorylation enzyme.

1 19. The method as recited in claim 15 wherein the molecules are
2 DNA and the means to modify the molecules is a ligation reaction.

1 20. The method as recited in claim 29 wherein the DNA molecules
2 are contacted with ligase.

2/4

Fig. 2

DNA LENGTH, L	DNA FRAGMENTS		OLIGOMER LENGTH, m	THE NUMBER OF OLIGONUCLEOTIDES IN ARRAY									
	LENGTH, I	NUMBER, K		P=90%		P=95%		P=99%		η_1/n			
				N	n	N	n	N	n				
4000	256	16	6 7	96 191	59 41	125 248	77 53	192 382	119 82	0.61 0.89			
30000	256	120	7 8	931 956	780 348	1211 1243	1015 453	1861 1911	1560 697	0.35 0.79			
30000	4096	8	7 8	59 58	50 22	77 76	66 29	118 116	101 45	0.36 0.80			
100000	4096	25	8 9	169 216	133 69	220 281	173 90	338 431	266 139	0.43 0.82			
500000	4096	125	9 10	1028 959	881 369	1337 1248	1146 481	2056 1918	1763 739	0.33 0.78			
4000000	32768	125	11 12	779 1503	485 325	1013 1956	631 423	1557 3006	970 650	0.59 0.88			

1. 2. 3. 4. 5. 6.

3/4

Fig. 3





Fig. 4



4/4

Fig. 5





Fig. 6



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/23242

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 433/6, 91.2, 91.21; 436/94, 527, 528, 807, 809; 427/211; 536/23/1, 24.3, 24.31, 24.32, 24.33

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,503,980 A (CANTOR) 02 April 1996, column 17, lines 15-43.	1-20
Y	EPO, 649,852 A1 (HITACHI, LTD.) 26 April 1995, see entire document.	1-20
Y	EPO, 701,001 A2 (HITACHI, LTD.) 13 March 1996, see entire document.	1-20
Y	US 5,552,270 A (KHRAPKO et al) 03 September 1996, see entire document.	1-6
Y	US 5,512,439 A (HORNES et al) 30 April 1996, see entire document.	7-20
Y	US 5,474,895 A (ISHII et al) 12 December 1995, see entire document.	1-6

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 MARCH 1998

Date of mailing of the international search report

27 APR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY FREDMAN

Telephone No. (703) 308-0196

4/4

Fig. 5





Fig. 6



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/23242

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :Please See Extra Sheet. US CL :Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC																									
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91.2, 91.21; 436/94, 527, 528, 807, 809; 427/211; 536/23/1, 24.3, 24.31, 24.32, 24.33 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																									
C. DOCUMENTS CONSIDERED TO BE RELEVANT																									
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																							
Y	US 5,503,980 A (CANTOR) 02 April 1996, column 17, lines 15-43.	1-20																							
Y	EPO, 649,852 A1 (HITACHI, LTD.) 26 April 1995, see entire document.	1-20																							
Y	EPO, 701,001 A2 (HITACHI, LTD.) 13 March 1996, see entire document.	1-20																							
Y	US 5,552,270 A (KHRAPKO et al) 03 September 1996, see entire document.	1-6																							
Y	US 5,512,439 A (HORNES et al) 30 April 1996, see entire document.	7-20																							
Y	US 5,474,895 A (ISHII et al) 12 December 1995, see entire document.	1-6																							
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																									
<table border="0"><tr><td>* Special categories of cited documents:</td><td>* T</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>* A</td><td>document defining the general state of the art which is not considered to be of particular relevance</td><td>* X</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>* B</td><td>earlier document published on or after the international filing date</td><td>* Y</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>* L</td><td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>* A</td><td>document member of the same patent family</td></tr><tr><td>* O</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>* P</td><td>document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	* A	document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	* B	earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A	document member of the same patent family	* O	document referring to an oral disclosure, use, exhibition or other means			* P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
* A	document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																						
* B	earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																						
* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A	document member of the same patent family																						
* O	document referring to an oral disclosure, use, exhibition or other means																								
* P	document published prior to the international filing date but later than the priority date claimed																								
Date of the actual completion of the international search 16 MARCH 1998		Date of mailing of the international search report 27 APR 1998																							
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer JEFFREY FREDMAN Telephone No. (703) 308-0196																							

Form PCT/ISA/210 (second sheet) (July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/23242

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,237,016 A (GHOSH et al) 17 August 1993, see entire document.	1-20
A	US 5,525,464 A (DRMANAC et al) 11 June 1996, see entire document.	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/23242

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C12Q 1/68; C12P 19/34; G01N 33/553, 33/544; B05D 1/00; C07H 21/02, 21/04

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/6, 91.2, 91.21; 436/94, 527, 528, 807, 809; 427/211; 536/23/1, 24.3, 24.31, 24.32, 24.33

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, BIOSIS, AQUASCI, CANCERLIT, CAPLUS, EMBASE, TOXLINE, NLDB
search terms: polyacrylamide, hydrophobic, affinity, fractionation, separation, purification, ligase, immobilized, bound,
support matrix, array, isolation, DNA, RNA, protein, polypeptide, nucleic, oligo, probe, primer, polynucleotide,
hybridization, anneal

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)